# A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

Study · id `cardio:ct-nct03226899` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03226899](<https://clinicaltrials.gov/study/NCT03226899>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03226899

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 242 participants.

## Technical summary

Registry record NCT03226899. Randomized; triple masking; primary purpose treatment. Start 2017-07-19 (actual); primary completion 2019-02-25 (actual). Results posted on 2021-11-04.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 242 participants (enrolled count; ClinicalTrials.gov record NCT03226899, source copy `cardio:ctgov-nct03226899-2021-11-04`, retrieved 2026-10-26)
- Started: 2017-07-19 (actual) (ClinicalTrials.gov record NCT03226899, source copy `cardio:ctgov-nct03226899-2021-11-04`, retrieved 2026-10-26)
- Primary completion: 2019-02-25 (actual) (ClinicalTrials.gov record NCT03226899, source copy `cardio:ctgov-nct03226899-2021-11-04`, retrieved 2026-10-26)
- Completion: 2019-02-25 (actual) (ClinicalTrials.gov record NCT03226899, source copy `cardio:ctgov-nct03226899-2021-11-04`, retrieved 2026-10-26)
- Results first posted: 2021-11-04 (ClinicalTrials.gov record NCT03226899, source copy `cardio:ctgov-nct03226899-2021-11-04`, retrieved 2026-10-26)
- Countries: United States; Czechia; Hungary; Poland (ClinicalTrials.gov record NCT03226899, source copy `cardio:ctgov-nct03226899-2021-11-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03226899-2021-11-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
- Condition: Gout
- Condition: Chronic Kidney Disease (CKD)
- Intervention (Drug): Lesinurad
- Intervention (Drug): XOI
- Intervention (Drug): Placebo
- Intervention (Drug): colchicine
- Intervention (Drug): corticosteroids
- Lead sponsor: Ironwood Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Colchicine (`cardio:colchicine`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

## Provenance

Content hash: fa750549ae307b7ef35207f978fcd97bb1fa2f59d824569a774ec723b48f576a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
